ABSTRACT
BACKGROUND Testosterone products are increasingly being prescribed to males for a variety of possible health benefits but the causal relationship between testosterone and health-related outcomes is unclear. Evidence from well-powered randomized controlled trials are difficult to obtain, particularly regarding effects on long-term or adverse outcomes. We sought to determine the effects of genetically-predicted calculated free testosterone (CFT) on 23 health outcomes.
METHODS Genetic variants associated with CFT were determined from 136,531 white British males in the UK Biobank. One-sample and two-sample Mendelian randomization (MR) analyses were performed to infer the effects of genetically-predicted CFT on 23 health outcomes selected based on relevance with known or suspected effects of testosterone therapy.
FINDINGS In males from the UK Biobank, 81 independent genetic variants were associated with CFT levels at genome-wide significance (p<5×10−8). Each 0.1 nmol/L increase in genetically-predicted CFT was associated with clinical benefits on increased heel bone mineral density (0.053 SD; 95% CI = 0.038 to 0.068; p=8.77×10−12) and decreased body fat percentage (−1.86%; 95% CI = −2.35 to −1.37; p=1.56×10−13), and adverse effects on increased risk of prostate cancer (OR=1.28; 95% CI=1.11 to 1.49; p=1.0×10−3), risk of androgenic alopecia (OR=1.82; 95% CI = 1.55 to 2.14; p=3.52×10−13), risk of benign prostate hyperplasia (BPH) (OR=1.81; 95% CI = 1.34 to 2.44; p=1.05×10−4) and hematocrit percentage (1.49%; 95% CI = 1.24 to 1.74; p=3.49×10−32).
CONCLUSIONS Long-term elevated free testosterone levels cause prostate cancer, BPH, and hair loss while reducing body fat percentage and increasing bone density. It also has a neutral effect on type 2 diabetes, cardiovascular and cognitive outcomes. Well powered randomized trials are needed to address the effects of shorter term use of exogenous testosterone on these outcomes.
Competing Interest Statement
HCG reports research grants from Eli Lilly, AstraZeneca, Merck, Novo Nordisk, and Sanofi; honoraria for speaking from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, and Sanofi; and consulting fees from Abbott, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck, Novo Nordisk, Janssen, Sanofi, Kowa, and Cirius. No other potential conflicts of interest relevant to this article were reported.
Funding Statement
MC was supported by a CIHR Frederick Banting and Charles Best Canada Graduate Scholarships Doctoral Award. MP was supported by the E.J. Moran Campbell Internal Career Research Award from McMaster University. RWM was supported by a CIHR Fellowship. HCG was supported by the McMaster-Sanofi Population Health Institute Chair in Diabetes Research and Care. GP was supported by the Canada Research Chair in Genetic and Molecular Epidemiology and the Cisco Systems Professorship in Integrated Health Biosystems. The funders had no role in the design, analyses, interpretation of results, writing of the paper, or decision for publication.
Author Declarations
All relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Not Applicable
Any clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.
Not Applicable
I have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.
Not Applicable
Data Availability
Associations of genetic variants with calculated free testosterone in the UK Biobank are provided in the supplementary data. All other UK Biobank data is available by application directly to the UK Biobank. All other genome-wide association study summary statistics are publicly-available from the corresponding consortia: CARDIoGRAMplusC4D (http://www.cardiogramplusc4d.org/data-downloads/), DIAGRAM (https://www.diagram-consortium.org/downloads.html), IGAP (http://web.pasteur-lille.fr/en/recherche/u744/igap/igap_download.php), MEGASTROKE (http://www.megastroke.org/download.html), and PRACTICAL (http://practical.icr.ac.uk/blog/?page_id=8164).
http://www.cardiogramplusc4d.org/data-downloads/
https://www.diagram-consortium.org/downloads.html
http://web.pasteur-lille.fr/en/recherche/u744/igap/igap_download.php
